The company continues to build validation data and believes its lower cost proposition can help it gain leverage in the European market where molecular tests are not reimbursed.

The Maryland-based firm reported in a recent proof-of-concept study that It used protease biomarkers to identify patients ...

The test is approved for patients with endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.

The researchers used the CellSearch assay to measure circulating tumor cells and determine the response to certain treatments as well as survival outcomes.

The company aims to streamline its own lab operations while also enabling distribution of its Alzheimer's tests to outside ...

The agreement's goal is to bring a blood-based test to market to stratify patients with traumatic brain injuries.

NowDx's First to Know Syphilis Test received FDA authorization in August, making it the first over-the-counter syphilis test to be authorized by the agency.

Deck: Xgenera has also closed a round of seed financing worth £500,000 and commenced a partnership with YouSeq, a UK technology firm.

CyPath Lung is a laboratory-developed assay that uses self-collected sputum samples treated with a fluorescent compound that preferentially binds to cancer cells and cancer-related cells, San ...

The US Food and Drug Administration granted marketing clearances for multiple infectious disease tests and a blood culture sample preparation system, among other devices.

The San Francisco-based firm will use the proceeds to accelerate commercialization of its Intellisep rapid sepsis test.

Last week, readers were most interested in a story about a new respiratory test launched by Roche leveraging a new PCR technology.